norgestimate Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Norgestimate is a steroidal progestin of the 19-nortestosterone group that is used in combination with ethinylestradiol as an oral contraceptive and for treatment of acne. and in combination with estradiol in menopausal hormone replacement therapy. Norgestimate shows high selectivity for the progesterone receptor and low androgenic activity.   NCATS

Chemistry

  • SMILES: CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C
  • InChIKey: KIQQMECNKUGGKA-NMYWJIRASA-N
  • Mol. Mass: 369.4971
  • ALogP: 4.71
  • ChEMBL Molecule:
    norgestimate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Combination drugs

( ethinyl estradiol (Estinyl), norgestimate - other names: estarylla, mili, mono-linyah, ortho tri-cyclen, ortho tri-cyclen lo, previfem, sprintec, tri-estarylla, tri-linyah, tri-lo-estarylla, tri-lo-linyah, tri-lo-mili, tri lo sprintec, tri-mili, tri-previfem, tri-sprintec )
|
( estradiol (progynon depot), norgestimate )

Alternative names

(+)-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester) | (17alpha)-17-(acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime | d-13beta-ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime | dexnorgestrel acetime | norgestimate | norgestimato | norgestimatum | norgestrel oxime acetate | orf-10131 | rwj-10131

Organizations (50)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (36)

Approved Indications (2)


 

Acne Vulgaris

Postmenopause (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (35)


 

Acne Vulgaris (Phase 4)

Cardiovascular Diseases (Phase 4)

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Phase 3)

Contraception (Phase 4)

Contraception Behavior (Phase 4)

Contraceptives, Oral (Phase 1)

Cystic Fibrosis (Phase 1)

Depressive Disorder, Major (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Drug Interactions (Phase 1)

Embryo Transfer (Phase 1)

Endometriosis (Phase 3)

Healthy Volunteers (Phase 1)

Heart Disease Risk Factors (Phase 4)

Hepacivirus (Phase 1)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

HIV (Phase 1)

HIV Infections (Phase 1)

Insulin Resistance (Phase 4)

Live Birth (Phase 4)

Menopause (Phase 4)

Metabolic Syndrome (Phase 4)

Metrorrhagia (Phase 2)

Nervous System Malformations (Phase 3)

Neural Tube Defects (Phase 3)

Obesity (Phase 4)

Osteoporosis (Phase 2)

Ovarian Diseases (Phase 2/Phase 3)

Pelvic Pain (Phase 3)

Pharmacokinetics (Phase 1)

Polycystic Ovary Syndrome (Phase 4)

Pregnancy (Early Phase 1)

Pregnancy Complications (Early Phase 1)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue